We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.49%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$11.9B
AUM Growth
+$2.55B
(+27%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
28.34%
Holding
1,181
New
44
Increased
774
Reduced
301
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$294M |
| 2 |
Apple
AAPL
|
+$74.6M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$68.1M |
| 4 |
Tesla
TSLA
|
+$64.9M |
| 5 |
Microsoft
MSFT
|
+$51.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$12.3M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$8.37M |
| 3 |
CLR
CONTINENTAL RESOURCES INC.
CLR
|
+$7.53M |
| 4 |
ASML
ASML
|
+$7.05M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$6.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.81% |
| 2 | Financials | 13.96% |
| 3 | Healthcare | 11.37% |
| 4 | Energy | 7.72% |
| 5 | Consumer Discretionary | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRO
176
DELISTED
Akero Therapeutics
AKRO
| $10.3M | 0.09% |
+187,799
| New | +$8.05M |
|
177
Linde
LIN
$235B
| $10.2M | 0.09% |
31,345
+11,183
| +55% | +$3.51M |
|
178
Willis Towers Watson
WTW
$31.7B
| $10.2M | 0.09% |
41,645
+3,876
| +10% | +$886K |
|
179
Oneok
OKE
$56.1B
| $10.1M | 0.08% |
153,275
+15,671
| +11% | +$963K |
|
180
Altimmune
ALT
$580M
| $9.85M | 0.08% |
598,887
+298,556
| +99% | +$3.35M |
|
181
iShares MSCI South Korea ETF
EWY
$22.5B
| $9.84M | 0.08% |
174,302
+23,151
| +15% | +$1.27M |
|
182
Huntington Bancshares
HBAN
$34.5B
| $9.84M | 0.08% |
698,076
+1,830
| +0.3% | +$26.5K |
|
183
Regions Financial
RF
$26.3B
| $9.79M | 0.08% |
454,001
+5,172
| +1% | +$112K |
|
184
T. Rowe Price
TROW
$25.6B
| $9.76M | 0.08% |
89,452
+8,027
| +10% | +$908K |
|
185
CSX Corp
CSX
$93B
| $9.75M | 0.08% |
314,707
-10,871
| -3% | -$327K |
|
186
Mondelez International
MDLZ
$80.5B
| $9.57M | 0.08% |
143,566
-6,566
| -4% | -$415K |
|
187
Walt Disney
DIS
$167B
| $9.57M | 0.08% |
110,110
+50,595
| +85% | +$4.84M |
|
188
Citizens Financial Group
CFG
$30.3B
| $9.51M | 0.08% |
241,672
-2,669
| -1% | -$104K |
|
189
Prologis
PLD
$136B
| $9.5M | 0.08% |
84,230
+40,275
| +92% | +$4.46M |
|
|
HZNP
190
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $9.43M | 0.08% |
82,885
-22,000
| -21% | -$1.83M |
|
191
Nike
NKE
$62.7B
| $9.42M | 0.08% |
80,466
+37,260
| +86% | +$3.75M |
|
192
General Dynamics
GD
$103B
| $9.4M | 0.08% |
37,897
+10,441
| +38% | +$2.55M |
|
193
Cognizant
CTSH
$24.3B
| $9.38M | 0.08% |
164,056
-13,319
| -8% | -$781K |
|
|
PR
194
Permian Resources
PR
$17.6B
| $9.32M | 0.08% |
991,313
-7,774
| -0.8% | -$74.4K |
|
195
Hartford Financial Services
HIG
$39.2B
| $9.29M | 0.08% |
122,544
+11,564
| +10% | +$833K |
|
196
Ovintiv
OVV
$17B
| $9.26M | 0.08% |
182,516
+30,841
| +20% | +$1.61M |
|
197
Verizon
VZ
$193B
| $9.25M | 0.08% |
234,766
+116,833
| +99% | +$4.4M |
|
|
CPE
198
DELISTED
Callon Petroleum Company
CPE
| $9.25M | 0.08% |
249,279
+61,563
| +33% | +$2.53M |
|
199
Ultragenyx Pharmaceutical
RARE
$2.56B
| $9.19M | 0.08% |
198,300
+57,610
| +41% | +$2.27M |
|
|
CPRX
200
DELISTED
Catalyst Pharmaceutical
CPRX
| $9.16M | 0.08% |
492,451
+87,742
| +22% | +$1.35M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Rafferty Asset Management held 1,181 positions worth $11.9B, up 27% from $9.4B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q4 2022, opening 44 new positions and adding to 774 existing holdings. Its largest new stake was Akero Therapeutics: 187,799 shares worth $10.3M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 38% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Microchip Technology, an estimated $12.3M trimmed.
- Rafferty Asset Management's largest Q4 2022 buy was Akero Therapeutics: 187,799 shares worth $10.3M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q4 2022, an estimated $294M increase.
- Rafferty Asset Management's biggest Q4 2022 reduction was Microchip Technology, cutting an estimated $12.3M.
- Rafferty Asset Management fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $7.53M.
- Rafferty Asset Management's ten largest holdings make up 28% of its $11.9B portfolio in Q4 2022.
- Rafferty Asset Management opened 44 new positions and closed 61 in Q4 2022.
- Rafferty Asset Management's portfolio value rose 27% quarter-over-quarter to $11.9B.
Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.